NZYM B Novozymes A/S Class B

Invitation to the annual shareholders’ meeting

Invitation to the annual shareholders’ meeting

The annual shareholders’ meeting will be held on

Tuesday April 30, 2024 at 4:00 pm CET at Bella Center, Center Boulevard 5, Denmark.

The distribution of profit will be addressed at the meeting and the Board of Directors proposes an ordinary dividend of DKK 2 or EUR 0.27 per A/B share for the last four months (September 1 - December 31) of 2023. This equals a pay-out ratio of 53.2% of Novonesis’ adjusted net profit for the four-month period.

Following the approval of the proposed dividend, legacy Novozymes shareholders will have received a total pay-out of the 2023 adjusted net profit of DKK 6.20 per share (50.8% pay-out ratio). This equals an increase in the paid dividend of 3% compared to the dividend paid for the 2022 result.

The invitation to convene the annual shareholders’ meeting is attached in English and Danish.

Attachments



EN
08/04/2024

Underlying

NZYM BNovozymes A/S Class B

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Novozymes A/S Class B

 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Major shareholder announcement

Major shareholder announcement Please read the full announcement in PDF. Attachments

July 21, 2025 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Biosolutions could create more than 600,000 jobs and unlock hundreds o...

Biosolutions could create more than 600,000 jobs and unlock hundreds of billions in growth for Europe Biosolutions could create more than 600,000 jobs and unlock hundreds of billions in growth for Europe A new report reveals that biosolutions could generate EUR 133 billion in economic gains and create over 600,000 jobs across all of Europe by 2035. But without urgent policy leadership and better regulation, Europe risks becoming the world’s best lab for solutions that scale elsewhere. Copenhagen, Denmark – 7 July 2025: Europe is on the verge of a job and growth boom if bio...

July 7, 2025 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Transactions under Novonesis’ share buyback program

Transactions under Novonesis’ share buyback program Novonesis has now completed the announced share buyback program of B shares worth up to EUR 100 million (DKK 746 million) in total during 2025. As of June 27th, 2025, Novonesis has purchased an accumulated  1,729,099 shares with a transaction value of DKK 745,2 million under the share buyback program announced by Novonesis in Company announcement No. 3, 2025 and initiated on March 5, 2025. Please read the full announcement in PDF. Attachment

June 30, 2025 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Transactions under Novonesis’ share buyback program

Transactions under Novonesis’ share buyback program As of June 20th, 2025, Novonesis has purchased an accumulated 1,660,344 shares with a transaction value of DKK 713,0 million under the share buyback program announced by Novonesis in Company announcement No. 3, 2025 and initiated on March 5, 2025. Under the program, Novonesis will buy back B shares worth up to EUR 100 million (DKK 746 million) in total during the remainder of 2025. Please read the full announcement in PDF  Attachment

June 23, 2025 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Major shareholder announcement

Major shareholder announcement Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital attached to shares and share capital through financial instruments. Per June 19, 2025, BlackRock, Inc. has adjusted its holding of shares to an equivalent of 23,343,678 shares, corresponding to 4.98% (previously 5.02%) of the total share capital attached to shares. The combined total of share capital attached to shares and share capital through financial instruments i...

June 23, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch